Neoadjuvant long-course chemoradiation remains strongly favored over short-course radiotherapy by radiation oncologists in the United States.
Yvonne M MoweryJoseph K SalamaS Yousuf ZafarHarvey G MooreChristopher G WillettBrian G CzitoM Benjamin HopkinsManisha PaltaPublished in: Cancer (2016)
US radiation oncologists rarely use neoadjuvant SC-RT despite 3 randomized controlled trials demonstrating no significant differences in outcome compared with LC-CRT. Further research is necessary to determine whether longer follow-up coupled with the benefits of lower cost, increased patient convenience, and lower acute toxicity will increase the adoption of SC-RT by radiation oncologists in the United States. Cancer 2017;123:1434-1441. © 2016 American Cancer Society.
Keyphrases
- locally advanced
- rectal cancer
- papillary thyroid
- radiation induced
- squamous cell
- lymph node
- randomized controlled trial
- advanced cancer
- early stage
- oxidative stress
- liver failure
- case report
- lymph node metastasis
- systematic review
- clinical trial
- heart failure
- respiratory failure
- childhood cancer
- intensive care unit
- young adults
- mass spectrometry
- drug induced
- high resolution
- hepatitis b virus
- aortic dissection
- study protocol
- solid phase extraction
- tandem mass spectrometry
- mechanical ventilation